Get the Stockscreener App
8.21
1.32%
-0.11
After Hours:
8.35
0.14
+1.71%
Xeris Biopharma Holdings Inc stock is traded at $8.21, with a volume of 873.43K.
It is down -1.32% in the last 24 hours and up +6.76% over the past month.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
See More
Previous Close:
$8.32
Open:
$8.4
24h Volume:
873.43K
Relative Volume:
0.48
Market Cap:
$1.42B
Revenue:
$314.85M
Net Income/Loss:
$12.01M
P/E Ratio:
125.34
EPS:
0.0655
Net Cash Flow:
$47.52M
1W Performance:
-4.53%
1M Performance:
+6.76%
6M Performance:
+9.32%
1Y Performance:
+63.55%
1-Day Range:
$8.20
$8.465
1-Week Range:
$8.1425
$8.83
52-Week Range:
$4.87
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
8.21 | 1.44B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Cash Flow - TradingKey
TradingKey - TradingKey
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xeris Biopharma Holdings Inc (XERS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xeris Biopharma Holdings, Inc. Revenue Breakdown – NASDAQ:XERS - TradingView
ETFs Investing in Xeris Biopharma Holdings, Inc. Stocks - TradingView
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Granahan Investment Management LLC - MarketBeat
XERS|Xeris Biopharma Holdings Inc|Price:8.320|Chg%:-0.090 - TradingKey
Xeris Biopharma Holdings Inc (XERS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xeris Biopharma Holdings Inc (XERS) Fundamental & Financial Data - Stocktwits
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - BioSpace
Xeris Biopharma to report Q2 2026 results on Aug 6 - scanx.trade
Press Release: Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Moomoo
Xeris Biopharma to report Q2 results, host conference call - Bitget
XERS5927663 Bond Coupon Profile — Rate & Payments - TradingView
XERS5927663 Bond Risk Profile - TradingView
XERS5927663 Bond Profile — Key Metrics - TradingView
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges - TipRanks
Xeris Biopharma (Nasdaq: XERS) ends 8% 2028 notes via cash and stock - Stock Titan
Emerald Mutual Fund Advisers Trust Acquires New Shares in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last? - Yahoo Finance
Price to earnings forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
Form 144 XERIS BIOPHARMA HOLDINGS For: 7 July By Investing.com - Investing.com Nigeria
Insider Sell: Steven Pieper Sells 45,000 Shares of Xeris Biophar - GuruFocus
Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com - Investing.com Nigeria
Xeris Biopharma (XERS) officer sells 45,000 shares under Rule 10b5-1 plan - Stock Titan
Steven Pieper sells 17,400 shares for $147,900 — XERS - Stock Titan
Enterprise value to EBITDA forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS - TradingView
Insider: 400-share purchase, 17,000 RSUs — XERS - Stock Titan
Xeris Biopharma Holdings Inc. (XERS) Q1 2026 Earnings: Surprise Profitability Drives 3.5% Stock Uptick - dars.gov.et
Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet MovesAnd What's Next - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Leads with High RSI of 84 - GuruFocus
Xeris Biopharma (XERS) Surges 3.5% as Biotech Momentum BuildsPrice Action Signals - dars.gov.et
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 3, 2026 - BioSpace
Xeris Biopharma Holdings (XERS) Patent Win Puts Its Valuation Back In Focus - Sahm
XERSXeris Biopharma Holdings Inc Options - Finviz
Beth Hecht Sells 16,666 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Form 4 Xeris Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Director at Xeris Biopharma (NASDAQ: XERS) receives stock and options grants - Stock Titan
Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3 - Stock Titan
Xeris Biopharma (XERS) officer sells 90,000 shares under 10b5-1 plan - Stock Titan
Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares - Stock Titan
Insider 10b5-1 sales scheduled at XERS: 16,667 shares on 05/01 and 06/01/2026 - Stock Titan
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Xeris names CEO John Shannon as Board Chair effective July 1, 2026 - scanx.trade
Xeris Pharmaceuticals appoints new director and board chair - TipRanks
Xeris Biopharma (NASDAQ: XERS) adds Nerissa Kreher and reshapes board - Stock Titan
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pieper Steven | See Remarks |
Jul 06 '26 |
Sale |
8.50 |
17,400 |
147,900 |
1,393,653 |
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):